Intravenous Immunoglobulin Market is driven by Increasing Adoption of (IVIG) Treatments

Intravenous Immunoglobulin Industry Overview

The global intravenous immunoglobulin market size was valued at USD 11.1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.3% from 2022 to 2030. The growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of intravenous immunoglobulin (IVIG) treatments, and rising use of off-label indications are the key drivers of the market. The rising number of patients with immunodeficiency disorders is the primary cause for the development of IVIG preparations.

The global IVIG market is expanding rapidly because of an increasing number of patients with bleeding issues and an increasing number of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients. Furthermore, increased investment in the healthcare industry is assisting in the growth of the IVIG market. Additionally, the growing number of patients suffering from autoimmune illnesses and other pathological conditions is fueling market expansion for IVIG products.

Gather more insights about the market drivers, restraints, and growth of the Global Intravenous Immunoglobulin market

The demand for IVIG therapies for the treatment of acquired and primary immunodeficiency diseases is increasing as it is the most effective and the only available treatment option. Moreover, sedentary lifestyle habits, including consumption of saturated fats, salt, and sugars, less physical activities, and high alcohol consumption have led to an increase in the prevalence of these diseases. The rising prevalence of lifestyle-associated disorders such as obesity and antibody deficiency disorders is expected to fuel the growth.

According to NIH data, over 500,000 persons in the U.S. suffer from more than 200 distinct types of primary immunodeficiency diseases (PIDDs). The rising prevalence of primary and acquired immunodeficiency illnesses including AIDS and X-linked hypogammaglobulinemia is projected to increase the demand for immunoglobulin therapy during the forecast period.

Furthermore, the rising cost of IVIG therapy is projected to be a significant barrier to market expansion. Immunoglobulin infusions are typically given once every 3 to 4 weeks, and the therapy is ongoing around 12-16 sessions yearly. The estimated cost of IVIG is USD 73.89 per gram, with a total cost of USD 10,000 depending on the severity of the illness. Immunoglobulin replacement treatments are long-term therapies that typically last 6 months. As per the ABIM Foundation, the expense of IgG treatment therapy exceeds USD 30,000 a year.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

Erythropoietin Drugs Market - The global erythropoietin drugs market size was valued at USD 6.87 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 1.5% from 2023 to 2030.

Diabetic Foot Ulcer Treatment Market - The global diabetic foot ulcer treatment market size was valued at USD 4.67 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030.

Intravenous Immunoglobulin Market Segmentation

Grand View Research has segmented the global intravenous immunoglobulin market on the basis of application, type, distribution channel, and region:

Intravenous Immunoglobulin Application Outlook (Revenue, USD Million, 2018 - 2030)

• Hypogammaglobulinemia
• CIDP
• Immunodeficiency Diseases
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• ITP
• Kawasaki Disease
• Guillain-Barre Syndrome
• Others

Intravenous Immunoglobulin Market Type Outlook (Revenue, USD Million, 2018 - 2030)

• IgG
• IgM
• IgA
• IgE
• IgD

Intravenous Immunoglobulin Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy
• Specialty Pharmacy
• Others

Intravenous Immunoglobulin Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)

Market Share Insights

April 2022: Grifols S.A. completed its purchase of Biotest, a significant and transformative deal that will boost growth and innovation. Grifols' purchase of Biotest AG allows it to accelerate and extend its product range, boost patient access to plasma medicines, operate the biggest private European network of plasma facilities (87 sites), and boost revenue growth and margin development.

Key Companies profiled:

Some of the prominent players in the global Intravenous Immunoglobulin market include:

• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc.

Order a free sample PDF of the Intravenous Immunoglobulin Market Intelligence Study, published by Grand View Research.